A Study of AT-02 in Subjects With Systemic Amyloidosis.

NCT ID: NCT05951049

Last Updated: 2025-08-24

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 120 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-09-21
• Study Completion Date: 2026-02-28

Brief Summary

This is a Phase 2 open-label extension study to evaluate the long-term safety, tolerability, and clinical activity of AT-02.

AT-02 is an investigational medicinal product being developed to treat systemic amyloidosis.

Detailed Description

The study will enroll subjects with systemic amyloidosis who have participated in AT02-001 study and will also directly enroll AL participants with renal disease who did not participate in study AT02-001.

The study includes screening period (56 days), treatment period (week 104), follow up (week 112).

The total duration of participant in study is up to 120 weeks.

A Safety Review Committee (SRC) will periodically convene and review all available clinical and laboratory data during the study. A single SRC will monitor safety across all AT-02 studies to ensure that safety signals are assessed in aggregate.

Conditions

Amyloidosis; Systemic

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

A (AT-02)

Subjects will receive AT-02 via intravenous infusion once every two or 4 weeks for 104 weeks (52 total AT-02 administrations).

Group Type: EXPERIMENTAL

AT02

Intervention Type: DRUG

Dosage Form: Solution for injection/infusion Dosage level: Different dose levels of AT02 Route of Administration: Intravenous use

Interventions

AT02

Dosage Form: Solution for injection/infusion Dosage level: Different dose levels of AT02 Route of Administration: Intravenous use

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Subject understands the study procedures and can give signed informed consent.

2. Subject is willing and able to comply with this protocol and will be available for the entire duration of the study.

3. Has a confirmed diagnosis of AL amyloidosis and meets the criteria below:

1. Histologic confirmation with a biopsy containing deposits of apple-green birefringent, Congophilic material or other amyloid staining (i.e., thioflavin T or sulfated alcian blue) with confirmatory immunohistochemistry or mass spectrometry, AND

2. May be receiving maintenance daratumumab and must have achieved and maintained a hematologic very good partial response (VGPR) or complete response (CR), have completed chemotherapy therapy (ie, melphalan, bortezomib, thalidomide, lenalidomide, or cyclophosphamide) and be at least 6 months from first hematologic response (CR or VGPR), AND

3. Either

<!-- -->

1. Screening eGFR ≥20 and ≤75 mL/min/1.73m2 based on CKD-EPI equation, OR

2. Proteinuria that is not improving (e.g., <25% reduction in urine protein creatinine ratio (UPCR) in the last 12 months or since hematologic response, whichever is shorter) with screening urine albumin creatinine ratio (UACR) >700 mg/g based on central lab assessment of first morning void urine collected at screening and confirmed by a separate Screening 24-hr urine protein >1.0gm/day; 24-hr urine protein may be repeated once during Screening.

Note: Participants may meet both eGFR and proteinuria criteria

4. Women of childbearing potential (WOCBP):

1. WOCBP must have a negative serum or urine pregnancy test within 24 hours prior to the start of study treatment.

2. Must not be breastfeeding, lactating, or planning a pregnancy during the study period.

3. WOCBP who are not exclusively in same-sex relationships must agree to remain abstinent (complete avoidance of heterosexual intercourse) or use adequate contraceptive methods, defined as use of a condom by the male partner combined with use of a highly effective method of contraception by the female partner, during the treatment period and for at least 105 days after the last dose of study intervention.

5. Women of non-childbearing potential (WONCBP), and female participants with vasectomized male partners:

1. WONCBP must agree to remain abstinent (complete avoidance of intercourse) or the male partners of WONCBP participants must wear a condom to protect against the transfer of study intervention through bodily fluids during the treatment period and for at least 105 days after the last dose of study intervention.

2. Postmenopausal females must have a documented serum FSH level >40 mIU/mL at Screening to confirm menopause.

6. Male participants:

1. Male participants must inform their female sexual partners who are WOCBP of the contraceptive requirements of the protocol and are expected to adhere to using contraception with their partner.

2. Male participants with female sexual partners who are WOCBP must agree to remain abstinent (complete avoidance of heterosexual intercourse) or use adequate contraceptive methods, defined as use of a condom by the male partner combined with use of a highly effective method of contraception by the female partner, during the treatment period and for at least 165 days after the last dose of study intervention.

3. Male participants must not donate sperm for at least 165 days after the last dose of study intervention.

4. Male participants in same-sex relationships or in relationships with WONCBP, must agree to remain abstinent (complete avoidance of intercourse) or use a condom to prevent exposure of the partner to study intervention through ejaculate/seminal fluid during the treatment period and for at least 165 days after the last dose of study intervention.

Exclusion Criteria

1. Receiving hemodialysis or peritoneal dialysis.

2. Myocardial infarction within 3 months of Screening.

3. New York Heart Association Class IV heart failure.

4. Kidney disease not caused by AL amyloidosis.

5. Respiratory insufficiency requiring oxygen therapy.

6. Currently receiving: melphalan, bortezomib, thalidomide, lenalidomide, or cyclophosphamide.

7. Currently receiving unfractionated heparin or heparin analogs (e.g., enoxaparin, dalteparin).

8. Active malignancy with exception of basal cell carcinoma of the skin, curatively resected squamous cell carcinoma of the skin, curatively treated in situ cervical cancer, non-metastatic prostate adenocarcinoma stably managed on hormonal therapy by medical oncologist or for which appropriate management is observation alone.

9. Uncontrolled or active infection.

10. Autoimmune disease requiring treatment with immunosuppressive/modulating treatment in the last year.

11. History of solid organ transplantation.

12. Suspected or known substance abuse disorder(s), serious psychiatric or any other medical condition, which, in the opinion of the Investigator, makes the participant unsuitable.

13. Has any concurrent illness that, in the opinion of the Investigator, might confound the results of the study or pose additional risk to the participant.

14. Screening alanine transaminase (ALT) or aspartate transaminase (AST) is >2.5x upper limit of normal (ULN).

15. Screening estimated creatinine clearance/eGFR using the CKD-EPI equation is <20 mL/min/1.73 m2.

16. Currently participating in an interventional clinical study or has participated in another interventional clinical study within the last four (4) weeks or within five (5) half-lives of the prior study treatment, whichever is longer. This exclusion does not apply to clinical studies in which the only investigational product is a diagnostic agent.

17. Any contraindication to MRI.

18. Hypersensitivity to AT-02 or any of its excipients.

19. Brain MRI performed within 6 months of Screening, or during the Screening period, that shows evidence of any of the following:

1. Acute or sub-acute hemorrhage.

2. Prior macrohemorrhage (defined as >1 cm in diameter on T2* sequence or susceptibility-weighted imaging (SWI)) or prior subarachnoid hemorrhage unless it can be documented that the finding is not due to an underlying structural or vascular abnormality (i.e., finding does not suggest participant is at risk of recurrent hemorrhage).

3. Greater than 4 microhemorrhages (defined as <1 cm in diameter on T2* sequence or SWI).

4. Cortical infarct (defined as >1.5 cm in diameter; irrespective of anatomic location).

5. >1 lacunar infarct (defined as <1.5 cm in diameter).

6. Superficial siderosis.

7. Any finding that, in the opinion of the Investigator, might pose a risk to the participant.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Novotech (Australia) Pty Limited

INDUSTRY

Sponsor Role: collaborator

Attralus, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Kansas City

Kansas City, Kansas, United States

Site Status: RECRUITING

Cleveland Clinic

Cleveland, Ohio, United States

Site Status: RECRUITING

OHSU (Oregon Health & Science University)

Portland, Oregon, United States

Site Status: NOT_YET_RECRUITING

Penn Presbyterian Medical Center

Philadelphia, Pennsylvania, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Scott Stephens

Role: CONTACT

sstephens@attralus.com

+1-321-228-7400

Deepika Aggarwal

Role: CONTACT

deepika.aggarwal@novotech-cro.com

3 9960 7997 ext. +61

Facility Contacts

Brett W. Sperry, Dr

Role: primary

Mazen Hanna, Dr

Role: primary

hannam@ccf.org

Ahmad Masri

Role: primary

masria@ohsu.edu

Brian Drachman, Dr

Role: primary

drachman@pennmedicine.upenn.edu

Other Identifiers

AT02-003

Identifier Type: -

Identifier Source: org_study_id